Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioadaptives (BDPT) EBT Margin (2019 - 2025)

Historic EBT Margin for Bioadaptives (BDPT) over the last 7 years, with Q3 2025 value amounting to 8193.05%.

  • Bioadaptives' EBT Margin changed N/A to 8193.05% in Q3 2025 from the same period last year, while for Sep 2025 it was 14561.8%, marking a year-over-year decrease of 124186400.0%. This contributed to the annual value of 5478.48% for FY2024, which is 41068200.0% down from last year.
  • As of Q3 2025, Bioadaptives' EBT Margin stood at 8193.05%.
  • Bioadaptives' EBT Margin's 5-year high stood at 646.13% during Q3 2021, with a 5-year trough of 27113.63% in Q2 2024.
  • Its 5-year average for EBT Margin is 5893.72%, with a median of 4982.5% in 2022.
  • As far as peak fluctuations go, Bioadaptives' EBT Margin tumbled by -224876400bps in 2024, and later surged by 222079400bps in 2025.
  • Quarter analysis of 5 years shows Bioadaptives' EBT Margin stood at 8006.65% in 2021, then soared by 63bps to 2933.01% in 2022, then surged by 52bps to 1398.89% in 2023, then tumbled by -1838bps to 27113.63% in 2024, then soared by 70bps to 8193.05% in 2025.
  • Its EBT Margin was 8193.05% in Q3 2025, compared to 4905.68% in Q2 2025 and 27113.63% in Q2 2024.